Navigation Links
Spaulding Clinical Welcomes Dr. Aziz Karim, Clinical Pharmacokinetic Consultant
Date:4/11/2011

WEST BEND, Wis., April 11, 2011 /PRNewswire/ -- Leading-edge Clinical Pharmacology and Cardiac Core Lab provider, Spaulding Clinical Research, LLC proudly announces the addition of Aziz Karim, BPharm, PhD, FCP, ABCP to their team as a consultant and advisor to Spaulding's Clinical Pharmacology/Pharmacokinetic department.  

Dr. Karim's expertise lies in the principles of Clinical Pharmacology and rational drug development including the design of drug-drug interaction and bioavailability/bioequivalence studies. With over 30 years of experience in Pharmaceutical Sciences and Clinical Pharmacology, he has contributed to the development and marketing approvals of over 30 NCEs and/or Novel Drug Delivery Systems and has interfaced extensively with global regulatory bodies.  Most recently, Dr. Karim was the Vice President of Global Clinical Pharmacology at Takeda Pharmaceuticals.  Prior to Takeda, he held the role of Distinguished Scientist & Senior Director of Clinical Pharmacology for G.D. Searle & Co. and Pharmacia.

Daniel Selness, General Manager and Senior Vice President of Operations, commented, "Aziz's understanding of early clinical development, ability to design appropriate pharmacology trials/programs, and analysis expertise are wonderful complements to our existing services. Pharmacokinetic design and analysis is an imperative part of NCE development and if not approached correctly, may result in significant delays to programs.  Keeping with our company goals, his experience will continue to improve clinical trials, ultimately leading to safer drugs in the marketplace." 

CEO Randol Spaulding stated, "The addition of Aziz's experience and skills furthers our ability to be a 'one-stop-shop' for pharmaceutical companies throughout the world.  We continue to focus on being the innovation leader in the industry."

To learn more about how Spaulding can assist with your Clinical Pharmacology programs or Pharmacokinetic analysis, please contact us at SpauldingPK@spauldingclinical.com or 262-306-3331.  Spaulding Clinical will be demonstrating their cutting edge "Spaulding IQ" ECG device and Protocol from June 19 – 22, 2011 in booth 1905 at the DIA meeting in Chicago, Illinois. 

About Spaulding Clinical

Spaulding Clinical Research, LLC (www.spauldingclinical.com) is a Clinical Pharmacology Research Unit and Cardiac Core Lab that offers a full range of global services from study design through study execution/conduct, data management, statistical analysis, and clinical summary/expert reporting. Spaulding has extensive experience conducting TQT, first-in-human, multiple rising dose, bioavailability/bioequivalence, drug interaction, and food effect studies. As a Phase 1-4 Core Lab provider, Spaulding offers the complete suite of equipment provisioning and electrocardiogram over-reading services with state-of-the-art technologies and expertly trained cardiologists.


'/>"/>
SOURCE Spaulding Clinical Research, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
2. Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
3. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
4. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
5. Boston Scientific Begins International Clinical Trial Enrollment for INNOVA™ Self-Expanding Bare-Metal Stent System
6. OmniComm Systems Awarded 4 Clinical Trials from U.S. Biotechnology Company
7. Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors
8. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
9. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
10. Data From Landmark Clinical Trial of Abbotts MitraClip® System Demonstrate Durable Clinical Benefits for Patients With Mitral Regurgitation Two Years After Treatment
11. Publication in SLEEP Journal Demonstrates Positive Results of Large Multi-Center Clinical Trial for Provent® Sleep Apnea Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... -- IRIDEX Corporation (NASDAQ: IRIX ) today announced ... stock, $0.01 par value (the "Offering" with such shares being ... terms of the Offering will depend on market and other ... no assurance as to whether or when the Offering may ... proceeds it will receive from this offering for working capital ...
(Date:12/8/2016)... 8, 2016 Global Interventional Radiology Market: ... global interventional radiology market analyzes the current and ... an elaborate executive summary, including a market snapshot ... sub-segments. The research is a combination of ... bulk of our research efforts along with information ...
(Date:12/8/2016)... -- Eli Lilly and Company (NYSE: LLY ) ... trial at the 9 th Clinical Trials on ... not meet the primary endpoint in the EXPEDITION3 clinical ... mild dementia due to Alzheimer,s disease (AD), and Lilly ... treatment of mild dementia due to AD. ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s ... groups, has aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced ... J. Hennessy, Jr said, “CURE Media Group is honored to team up with Upstage ...
(Date:12/8/2016)... ... December 08, 2016 , ... Launching of ... Unified Instance Manager architecture, meeting the needs of multichannel growth and doubling ... unattended auto-dialing system without agents, Presence Robodialer, provides greater operational capacity, administrative ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... surgery as possible. With this in mind, SIGVARIS has created a new line ... clot) during bed rest and provide the benefits of graduated compression when transitioning ...
(Date:12/8/2016)... ... 08, 2016 , ... The Dan Carlisle Agency, an Alabama-owned ... is announcing the launch of a charity drive to raise support and awareness ... and children in Birmingham has grown steadily since the 1980’s, and the Pathways ...
Breaking Medicine News(10 mins):